Andreas Bergmann

机构：Max Planck Institute for Plasma Physics · ORCID：0000-0002-4466-1682

发表论文 355 篇 · 总被引 12818 次 · h-index 62

代表论文

• Safety and tolerability of non-neutralizing adrenomedullin antibody adrecizumab (HAM8101) in septic shock patients: the AdrenOSS-2 phase 2a biomarker-guided trial (2021 · Intensive Care Medicine · 被引 98)
• Monitoring circulating dipeptidyl peptidase 3 (DPP3) predicts improvement of organ failure and survival in sepsis: a prospective observational multinational study (2021 · Critical Care · 被引 89)
• Inhibition of circulating dipeptidyl-peptidase 3 restores cardiac function in a sepsis-induced model in rats: A proof of concept study (2020 · PLoS ONE · 被引 79)
• Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes (2023 · European Heart Journal · 被引 55)
• Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study (2022 · Diabetes Care · 被引 37)
• Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) (2020 · Biomolecules · 被引 28)